Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ohresser

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Medecine Sciences : M/S|December 29, 2009
[Neonatal Fc receptor, key control of immunoglobulins biodistribution]Charlotte Magdelaine-Beuzelin, Marc Ohresser, Hervé Watier
Lancet (London, England)|December 26, 2006
Risk in drug trialsMarc Ohresser, Daniel Olive, Bernard Vanhove, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodiesJulien Lejeune, Gilles Thibault, David Ternant, et al.
Blood|August 5, 2005
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodiesDavid Ternant, Marc Ohresser, Cécile Thomas, et al.
Bulletin Du Cancer|November 6, 2007
[Target antigens for therapeutic antibodies in oncology: many candidates, few successes]Nicolas Ceze, Alicia Probst, Thierry Lecomte, et al.
Mabs|October 4, 2012
FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian populationJulien Lejeune, Benoît Piègu, Valérie Gouilleux-Gruart, et al.
Cancer Research|February 19, 2008
Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotypeNicolas Congy-Jolivet, Armelle Bolzec, David Ternant, et al.
Critical Reviews in Oncology/Hematology|January 2, 2007
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatmentSeverine Loisel, Marc Ohresser, Marc Pallardy, et al.
Pharmacogenetics and Genomics|December 11, 2013
Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patientsDavid Ternant, Matthias Büchler, Gilles Thibault, et al.
Clinical Colorectal Cancer|November 21, 2017
Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?Sajida Ibrahim, Alban Girault, Marc Ohresser, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Medecine Sciences : M/S|December 29, 2009
[Neonatal Fc receptor, key control of immunoglobulins biodistribution]Charlotte Magdelaine-Beuzelin, Marc Ohresser, Hervé Watier
Lancet (London, England)|December 26, 2006
Risk in drug trialsMarc Ohresser, Daniel Olive, Bernard Vanhove, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodiesJulien Lejeune, Gilles Thibault, David Ternant, et al.
Blood|August 5, 2005
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodiesDavid Ternant, Marc Ohresser, Cécile Thomas, et al.
Bulletin Du Cancer|November 6, 2007
[Target antigens for therapeutic antibodies in oncology: many candidates, few successes]Nicolas Ceze, Alicia Probst, Thierry Lecomte, et al.
Mabs|October 4, 2012
FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian populationJulien Lejeune, Benoît Piègu, Valérie Gouilleux-Gruart, et al.
Cancer Research|February 19, 2008
Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotypeNicolas Congy-Jolivet, Armelle Bolzec, David Ternant, et al.
Critical Reviews in Oncology/Hematology|January 2, 2007
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatmentSeverine Loisel, Marc Ohresser, Marc Pallardy, et al.
Pharmacogenetics and Genomics|December 11, 2013
Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patientsDavid Ternant, Matthias Büchler, Gilles Thibault, et al.
Clinical Colorectal Cancer|November 21, 2017
Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?Sajida Ibrahim, Alban Girault, Marc Ohresser, et al.
Pageof 2